Trial Profile

A Phase I/IIa clinical trial of BW-40202 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Nov 2025 New trial record
15 Sep 2025 According to a Argo Biopharma media release, compnay today announced that the National Medical Products Administration of China (NMPA) has granted Investigational New Drug (IND) approval for a phase II clinical trial of BW-40202, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases and study is expected to commence in Jan 2026. The phase I/IIa IND approval was obtained from the NMPA in China in June 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com